查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1081113

全球癌症研究小鼠模型市場：北美約佔全球市場的一半

Market Study on Oncology Mice Models: North America Accounts for Nearly Half Global Market Share
出版日期: | 出版商: Persistence Market Research | 英文 250 Pages | 商品交期: 2-5個工作天內

價格

本報告調查全球癌症研究小鼠模型市場，分析市場概況、主要趨勢、對市場增長的各種影響因素、管道分析、法律和監管環境以及市場規模的變化。/地區/主要國家，競爭分析，主要公司概況等匯總。

目錄

第 1 章執行摘要

第 2 章市場概述

第 3 章主要市場趨勢

  • 影響市場的主要趨勢
  • 產品創新/發展趨勢

第 4 章關鍵成功因素

  • 癌症療法：管線分析
  • 癌症免疫治療藥物：管線分析
  • 繼續進行癌症免疫治療藥物臨床試驗的製藥公司名單
  • 參與正在進行的癌症免疫治療藥物臨床試驗的學術和研究機構名單
  • 臨床前 CRO 列表
  • 母市場分析
  • 癌症聯合治療的臨床試驗相對數量
  • 癌症免疫治療藥物的開發環境
  • 臨床前癌症免疫治療藥物模型列表
  • 主要監管場景
  • 波特分析
  • PESTLE 分析
  • 供應鏈分析

第 5 章市場背景

  • 宏觀經濟因素
  • 預測變量：相關性/影響
  • 市場動態
    • 促進因素
    • 抑制因素
    • 市場機會分析

第 6 章 COVID-19 分析

  • 當前的 COVID-19 統計數據/預期的未來影響
  • 當前 GDP 預測/預期影響
  • 當前經濟預測/與 2008 年經濟分析的比較
  • COVID-19 □ 影響分析
  • 復甦情景：短期、中期、長期影響

第 7 章全球癌症研究小鼠模型市場需求分析/預測

  • 過往市場分析
  • 當前和未來的市場預測

第 8 章全球癌症研究小鼠模型市場分析與預測：分產品

  • 簡介/主要發現
  • 過去的分析
  • 當前和未來的預測
    • 人源化免疫系統小鼠模型
    • 同義腫瘤小鼠模型
    • 免疫缺陷小鼠模型
    • NOG鼠標模型
    • 自發性腫瘤小鼠模型
    • 其他
  • 市場吸引力

第 9 章全球癌症研究小鼠模型市場分析與預測：按最終用戶分類

  • 簡介/主要發現
  • 過去的分析
  • 當前和未來的預測
    • CRO
    • 製藥公司/生物製藥公司
    • 學術/研究所
  • 市場吸引力

第 10 章全球癌症研究小鼠模型市場分析與預測：按地區劃分

  • 簡介/主要發現
  • 過去的分析
  • 當前和未來的預測
    • 北美
    • 拉丁美洲
    • 歐洲
    • 亞太地區
    • 中東/非洲
  • 市場吸引力

第 11 章北美癌症研究小鼠模型市場分析與預測

第 12 章拉丁美洲癌症研究小鼠模型市場分析與預測

第 13 章歐洲癌症研究小鼠模型市場分析與預測

第 14 章亞太地區癌症研究小鼠模型市場分析與預測

第 15 章中東和非洲癌症研究小鼠模型市場分析與預測

第 16 章癌症研究小鼠模型市場分析與預測：按國家/地區分類

  • 美國
  • 加拿大
  • 巴西
  • 阿根廷
  • 墨西哥
  • 德國
  • 義大利
  • 法國
  • 英國
  • 西班牙
  • 比荷盧國家
  • 俄羅斯
  • 中國
  • 日本
  • 印度
  • 澳大利亞/新西蘭
  • 海灣合作委員會國家
  • 南非

第 17 章市場結構分析

  • 市場分析：按公司層級
  • 主要公司的市場份額分析

第 18 章競爭分析

  • 競爭基準
  • 競爭性儀表板
  • 競技深潛
    • The Jackson Laboratory
    • Taconic Biosciences
    • Charles River Laboratories
    • Shanghai Model Organisms Center Inc.
    • Envigo
    • Biocytogen
    • Genoway
    • Crown Bioscience Inc.(JSR Corporation).
    • Cyagen
    • Applied stem cells
    • Ingenious Targeting Laboratory
    • PolyGene-Transgenic mice model company
    • Creative Biolabs
    • TransCure Bioservices
    • Champions Oncology Inc
    • Certis Oncology
    • Signature
    • Pharmaron
    • Laboratory Corporation of America Holdings
    • Gempharmatech
    • Janvier Labs
    • Harbour BioMed

第 19 章假設/首字母縮略詞

第 20 章調查方法

Product Code: PMRREP33046

Oncology Mice Models Market - Scope of Report

The latest publication by Persistence Market Research on the oncology mice models market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights on current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2032.

Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research's study. This research study can support readers to know the demand for oncology mice models and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the oncology mice models market. The insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the oncology mice models market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the oncology mice models market are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.

Key Market Segments

Persistence Market Research's study on the oncology mice models market offers information divided into three important segments - product, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Product

Humanized Immune System Mice Models

Syngeneic Tumor Mice Models

Immunodeficient Mice Models

NOG Mice Models

Spontaneous Tumor Mice Models

Others

End User

Contract Research Organizations

Pharma and Biopharma Companies

Academic and Research Institutes

Region

North America

Latin America

Europe

Asia Pacific

Middle East and Africa (MEA)

Key Questions Answered in Report

Which regions will continue to remain the most profitable markets for oncology mice models over the coming years?

How will changing trends impact the market?

How has the COVID-19 crisis impacted market growth?

How can market players capture the low-hanging opportunities in developed regions?

What are the strategies of stakeholders in the market to shape their position in this landscape?

What are the restraining factors that investors need to be aware of and might tackle while investing in the market?

What are the developmental trends that will impact the market?

How can companies in the oncology mice models market avail themselves the growth opportunities in developed and emerging sectors?

Research Methodology

In Persistence Market Research's study, a unique research methodology is utilized to conduct extensive research on the growth of the oncology mice models market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research's projections on the growth prospects of the oncology mice models market more accurate and reliable

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions & Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Oncology Drugs - Pipeline Analysis
    • 4.1.1. By Intervention
    • 4.1.2. By Phase
    • 4.1.3. By Funding Authority
  • 4.2. Immuno-Oncology Drugs - Pipeline Analysis
    • 4.2.1. By Phase
    • 4.2.2. By Funding Authority
  • 4.3. List of Pharma Companies That Have Ongoing Immuno-Oncology Clinical Trials
  • 4.4. List of Academic & Research Institutes Involved In Ongoing Immuno-Oncology Clinical Trials
  • 4.5. List of Preclinical CROs
  • 4.6. Parent Market Analysis
  • 4.7. Relative Number of Combination Oncology Therapy Trials
  • 4.8. Landscape of Immuno-Oncology Drug Development
  • 4.9. List of Preclinical immuno-oncology models
    • 4.9.1. Cell lines
    • 4.9.2. Mice Models
    • 4.9.3. Organoids/ spheroids
  • 4.10. Key Regulatory Scenario
  • 4.11. Porter's Analysis
  • 4.12. PESTLE Analysis
  • 4.13. Supply Chain Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Expenditure
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Covid-19 Pandemic
    • 5.2.2. Prevalence of cancer
    • 5.2.3. Rise in R&D investments
    • 5.2.4. Stringent Regulations
    • 5.2.5. Rise in number of pre-clinical and clinical studies
    • 5.2.6. Increasing investment in Cancer research
    • 5.2.7. GDP Growth
    • 5.2.8. Advancements in Models
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID19 Crisis Analysis

  • 6.1. Current COVID19 Statistics and Probable Future Impact
  • 6.2. Current GDP Projection and Probable Impact
  • 6.3. Current Economic Projection as compared to 2008 Economic analysis
  • 6.4. COVID19 and Impact Analysis
  • 6.5. Recovery Scenario - Short term, Midterm, and Long Term Impact

7. Global Oncology Mice Models Market Demand (in Value or Size in US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2017- 2021
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032, by Product

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Product, 2017-2021
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022-2032
    • 8.3.1. Humanized Immune System Mice Models
    • 8.3.2. Syngeneic Tumor Mice Models
    • 8.3.3. Immunodeficient Mice Models
    • 8.3.4. NOG Mice Models
    • 8.3.5. Spontaneous Tumor Mice Models
    • 8.3.6. Others
  • 8.4. Market Attractiveness Analysis By Product

9. Global Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032, by End User

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By End User, 2017-2021
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022-2032
    • 9.3.1. Contract Research Organizations
    • 9.3.2. Pharma and Biopharma Companies
    • 9.3.3. Academic and Research Institutes
  • 9.4. Market Attractiveness Analysis By Indication

10. Global Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032, by Region

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis By Region, 2017-2021
  • 10.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2032
    • 10.3.1. The North America
    • 10.3.2. Latin America
    • 10.3.3. Europe
    • 10.3.4. Asia Pacific
    • 10.3.5. Middle East and Africa (MEA)
  • 10.4 Market Attractiveness Analysis

11. North America Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
  • 11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
    • 11.3.1. By Country
    • 11.3.2. By Product
    • 11.3.3. By End User
  • 11.4. Market Attractiveness Analysis
  • 11.5. Key Market Participants - Intensity Mapping
  • 11.6. Drivers and Restraints - Impact Analysis

12. Latin America Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032

  • 12.1. Introduction / Key Findings
  • 12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
  • 12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
    • 12.3.1. By Country
    • 12.3.2. By Product
    • 12.3.3. By End User
  • 12.4. Market Attractiveness Analysis
  • 12.5. Key Market Participants - Intensity Mapping
  • 12.6. Drivers and Restraints - Impact Analysis

13. Europe Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032

  • 13.1. Introduction / Key Findings
  • 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
  • 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
    • 13.3.1. By Country
    • 13.3.2. By Product
    • 13.3.3. By End User
  • 13.4. Market Attractiveness Analysis
  • 13.5. Key Market Participants - Intensity Mapping
  • 13.6. Drivers and Restraints - Impact Analysis

14. Asia Pacific Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032

  • 14.1. Introduction / Key Findings
  • 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
  • 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
    • 14.3.1. By Country
    • 14.3.2. By Product
    • 14.3.3. By End User
  • 14.4. Market Attractiveness Analysis
  • 14.5. Key Market Participants - Intensity Mapping
  • 14.6. Drivers and Restraints - Impact Analysis

15. Middle East and Africa (MEA) Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032

  • 15.1. Introduction / Key Findings
  • 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
  • 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
    • 15.3.1. By Country
    • 15.3.2. By Product
    • 15.3.3. By End User
  • 15.4. Market Attractiveness Analysis
  • 15.5. Key Market Participants - Intensity Mapping
  • 15.6. Drivers and Restraints - Impact Analysis

16. Country Level Medical Cart Market Analysis and Forecast 2022 & 2032

  • 16.1. Introduction
    • 16.1.1. Market Value Proportion Analysis
    • 16.1.2. Global VS. Country Growth Comparison
  • 16.2. U.S. Medical Cart Market Analysis
    • 16.2.1. By Product
    • 16.2.2. By End User
  • 16.3. Canada Medical Cart Market Analysis
    • 16.3.1. By Product
    • 16.3.2. By End User
  • 16.4. Brazil Medical Cart Market Analysis
    • 16.4.1. By Product
    • 16.4.2. By End User
  • 16.5. Argentina Medical Cart Market Analysis
    • 16.5.1. By Product
    • 16.5.2. By End User
  • 16.6. Mexico Medical Cart Market Analysis
    • 16.6.1. By Product
    • 16.6.2. By End User
  • 16.7. Germany Medical Cart Market Analysis
    • 16.7.1. By Product
    • 16.7.2. By End User
  • 16.8. Italy Medical Cart Market Analysis
    • 16.8.1. By Product
    • 16.8.2. By End User
  • 16.9. France Medical Cart Market Analysis
    • 16.9.1. By Product
    • 16.9.2. By End User
  • 16.10. U.K. Medical Cart Market Analysis
    • 16.10.1. By Product
    • 16.10.2. By End User
  • 16.11. Spain Medical Cart Market Analysis
    • 16.11.1. By Product
    • 16.11.2. By End User
  • 16.12. BENELUX Medical Cart Market Analysis
    • 16.12.1. By Product
    • 16.12.2. By End User
  • 16.13. Russia Medical Cart Market Analysis
    • 16.13.1. By Product
    • 16.13.2. By End User
  • 16.14. China Medical Cart Market Analysis
    • 16.14.1. By Product
    • 16.14.2. By End User
  • 16.15. Japan Medical Cart Market Analysis
    • 16.15.1. By Product
    • 16.15.2. By End User
  • 16.16. India Medical Cart Market Analysis
    • 16.16.1. By Product
    • 16.16.2. By End User
  • 16.17. Australia and New Zealand Medical Cart Market Analysis
    • 16.17.1. By Product
    • 16.17.2. By End User
  • 16.18. GCC Countries Medical Cart Market Analysis
    • 16.18.1. By Product
    • 16.18.2. By End User
  • 16.19. South Africa Medical Cart Market Analysis
    • 16.19.1. By Product
    • 16.19.2. By End User

17. Market Structure Analysis

  • 17.1. Market Analysis by Tier of Companies
  • 17.2. Market Share Analysis of Top Players

18. Competition Analysis

  • 18.1. Competition Benchmarking
  • 18.2. Competition Dashboard
  • 18.3. Competition Deep Dive
    • 18.3.1. The Jackson Laboratory
      • 18.3.1.1. Overview
      • 18.3.1.2. Product Portfolio
      • 18.3.1.3. Key Financials
      • 18.3.1.4. SWOT Analysis
      • 18.3.1.5. Sales Footprint
      • 18.3.1.6. Strategy Overview
        • 18.3.1.6.1. Marketing Strategy
        • 18.3.1.6.2. Product Strategy
        • 18.3.1.6.3. Channel Strategy
    • 18.3.2. Taconic Biosciences
      • 18.3.2.1. Overview
      • 18.3.2.2. Product Portfolio
      • 18.3.2.3. Key Financials
      • 18.3.2.4. SWOT Analysis
      • 18.3.2.5. Sales Footprint
      • 18.3.2.6. Strategy Overview
        • 18.3.2.6.1. Marketing Strategy
        • 18.3.2.6.2. Product Strategy
        • 18.3.2.6.3. Channel Strategy
    • 18.3.3. Charles River Laboratories
      • 18.3.3.1. Overview
      • 18.3.3.2. Product Portfolio
      • 18.3.3.3. Key Financials
      • 18.3.3.4. SWOT Analysis
      • 18.3.3.5. Sales Footprint
      • 18.3.3.6. Strategy Overview
        • 18.3.3.6.1. Marketing Strategy
        • 18.3.3.6.2. Product Strategy
        • 18.3.3.6.3. Channel Strategy
    • 18.3.4. Shanghai Model Organisms Center Inc.
      • 18.3.4.1. Overview
      • 18.3.4.2. Product Portfolio
      • 18.3.4.3. Key Financials
      • 18.3.4.4. SWOT Analysis
      • 18.3.4.5. Sales Footprint
      • 18.3.4.6. Strategy Overview
        • 18.3.4.6.1. Marketing Strategy
        • 18.3.4.6.2. Product Strategy
        • 18.3.4.6.3. Channel Strategy
    • 18.3.5. Envigo
      • 18.3.5.1. Overview
      • 18.3.5.2. Product Portfolio
      • 18.3.5.3. Key Financials
      • 18.3.5.4. SWOT Analysis
      • 18.3.5.5. Sales Footprint
      • 18.3.5.6. Strategy Overview
        • 18.3.5.6.1. Marketing Strategy
        • 18.3.5.6.2. Product Strategy
        • 18.3.5.6.3. Channel Strategy
    • 18.3.6. Biocytogen
      • 18.3.6.1. Overview
      • 18.3.6.2. Product Portfolio
      • 18.3.6.3. Key Financials
      • 18.3.6.4. SWOT Analysis
      • 18.3.6.5. Sales Footprint
      • 18.3.6.6. Strategy Overview
        • 18.3.6.6.1. Marketing Strategy
        • 18.3.6.6.2. Product Strategy
        • 18.3.6.6.3. Channel Strategy
    • 18.3.7. Genoway
      • 18.3.7.1. Overview
      • 18.3.7.2. Product Portfolio
      • 18.3.7.3. Key Financials
      • 18.3.7.4. SWOT Analysis
      • 18.3.7.5. Sales Footprint
      • 18.3.7.6. Strategy Overview
        • 18.3.7.6.1. Marketing Strategy
        • 18.3.7.6.2. Product Strategy
        • 18.3.7.6.3. Channel Strategy
    • 18.3.8. Crown Bioscience Inc. (JSR Corporation).
      • 18.3.8.1. Overview
      • 18.3.8.2. Product Portfolio
      • 18.3.8.3. Key Financials
      • 18.3.8.4. SWOT Analysis
      • 18.3.8.5. Sales Footprint
      • 18.3.8.6. Strategy Overview
        • 18.3.8.6.1. Marketing Strategy
        • 18.3.8.6.2. Product Strategy
        • 18.3.8.6.3. Channel Strategy
    • 18.3.9. Cyagen
      • 18.3.9.1. Overview
      • 18.3.9.2. Product Portfolio
      • 18.3.9.3. Key Financials
      • 18.3.9.4. SWOT Analysis
      • 18.3.9.5. Sales Footprint
      • 18.3.9.6. Strategy Overview
        • 18.3.9.6.1. Marketing Strategy
        • 18.3.9.6.2. Product Strategy
        • 18.3.9.6.3. Channel Strategy
    • 18.3.10. Applied stem cells
      • 18.3.10.1. Overview
      • 18.3.10.2. Product Portfolio
      • 18.3.10.3. Key Financials
      • 18.3.10.4. SWOT Analysis
      • 18.3.10.5. Sales Footprint
      • 18.3.10.6. Strategy Overview
        • 18.3.10.6.1. Marketing Strategy
        • 18.3.10.6.2. Product Strategy
        • 18.3.10.6.3. Channel Strategy
    • 18.3.11. Ingenious Targeting Laboratory
      • 18.3.11.1. Overview
      • 18.3.11.2. Product Portfolio
      • 18.3.11.3. Key Financials
      • 18.3.11.4. SWOT Analysis
      • 18.3.11.5. Sales Footprint
      • 18.3.11.6. Strategy Overview
        • 18.3.11.6.1. Marketing Strategy
        • 18.3.11.6.2. Product Strategy
        • 18.3.11.6.3. Channel Strategy
    • 18.3.12. PolyGene - Transgenic mice model company
      • 18.3.12.1. Overview
      • 18.3.12.2. Product Portfolio
      • 18.3.12.3. Key Financials
      • 18.3.12.4. SWOT Analysis
      • 18.3.12.5. Sales Footprint
      • 18.3.12.6. Strategy Overview
        • 18.3.12.6.1. Marketing Strategy
        • 18.3.12.6.2. Product Strategy
        • 18.3.12.6.3. Channel Strategy
    • 18.3.13. Creative Biolabs
      • 18.3.13.1. Overview
      • 18.3.13.2. Product Portfolio
      • 18.3.13.3. Key Financials
      • 18.3.13.4. SWOT Analysis
      • 18.3.13.5. Sales Footprint
      • 18.3.13.6. Strategy Overview
        • 18.3.13.6.1. Marketing Strategy
        • 18.3.13.6.2. Product Strategy
        • 18.3.13.6.3. Channel Strategy
    • 18.3.14. TransCure Bioservices
      • 18.3.14.1. Overview
      • 18.3.14.2. Product Portfolio
      • 18.3.14.3. Key Financials
      • 18.3.14.4. SWOT Analysis
      • 18.3.14.5. Sales Footprint
      • 18.3.14.6. Strategy Overview
        • 18.3.14.6.1. Marketing Strategy
        • 18.3.14.6.2. Product Strategy
        • 18.3.14.6.3. Channel Strategy
    • 18.3.15. Champions Oncology Inc
      • 18.3.15.1. Overview
      • 18.3.15.2. Product Portfolio
      • 18.3.15.3. Key Financials
      • 18.3.15.4. SWOT Analysis
      • 18.3.15.5. Sales Footprint
      • 18.3.15.6. Strategy Overview
        • 18.3.15.6.1. Marketing Strategy
        • 18.3.15.6.2. Product Strategy
        • 18.3.15.6.3. Channel Strategy
    • 18.3.16. Certis Oncology
      • 18.3.16.1. Overview
      • 18.3.16.2. Product Portfolio
      • 18.3.16.3. Key Financials
      • 18.3.16.4. SWOT Analysis
      • 18.3.16.5. Sales Footprint
      • 18.3.16.6. Strategy Overview
        • 18.3.16.6.1. Marketing Strategy
        • 18.3.16.6.2. Product Strategy
        • 18.3.16.6.3. Channel Strategy
    • 18.3.17. Signature
      • 18.3.17.1. Overview
      • 18.3.17.2. Product Portfolio
      • 18.3.17.3. Key Financials
      • 18.3.17.4. SWOT Analysis
      • 18.3.17.5. Sales Footprint
      • 18.3.17.6. Strategy Overview
        • 18.3.17.6.1. Marketing Strategy
        • 18.3.17.6.2. Product Strategy
        • 18.3.17.6.3. Channel Strategy
    • 18.3.18. Pharmaron
      • 18.3.18.1. Overview
      • 18.3.18.2. Product Portfolio
      • 18.3.18.3. Key Financials
      • 18.3.18.4. SWOT Analysis
      • 18.3.18.5. Sales Footprint
      • 18.3.18.6. Strategy Overview
        • 18.3.18.6.1. Marketing Strategy
        • 18.3.18.6.2. Product Strategy
        • 18.3.18.6.3. Channel Strategy
    • 18.3.19. Laboratory Corporation of America Holdings
      • 18.3.19.1. Overview
      • 18.3.19.2. Product Portfolio
      • 18.3.19.3. Key Financials
      • 18.3.19.4. SWOT Analysis
      • 18.3.19.5. Sales Footprint
      • 18.3.19.6. Strategy Overview
        • 18.3.19.6.1. Marketing Strategy
        • 18.3.19.6.2. Product Strategy
        • 18.3.19.6.3. Channel Strategy
    • 18.3.20. Gempharmatech
      • 18.3.20.1. Overview
      • 18.3.20.2. Product Portfolio
      • 18.3.20.3. Key Financials
      • 18.3.20.4. SWOT Analysis
      • 18.3.20.5. Sales Footprint
      • 18.3.20.6. Strategy Overview
        • 18.3.20.6.1. Marketing Strategy
        • 18.3.20.6.2. Product Strategy
        • 18.3.20.6.3. Channel Strategy
    • 18.3.21. Janvier Labs
      • 18.3.21.1. Overview
      • 18.3.21.2. Product Portfolio
      • 18.3.21.3. Key Financials
      • 18.3.21.4. SWOT Analysis
      • 18.3.21.5. Sales Footprint
      • 18.3.21.6. Strategy Overview
        • 18.3.21.6.1. Marketing Strategy
        • 18.3.21.6.2. Product Strategy
        • 18.3.21.6.3. Channel Strategy
    • 18.3.22. Harbour BioMed
      • 18.3.22.1. Overview
      • 18.3.22.2. Product Portfolio
      • 18.3.22.3. Key Financials
      • 18.3.22.4. SWOT Analysis
      • 18.3.22.5. Sales Footprint
      • 18.3.22.6. Strategy Overview
        • 18.3.22.6.1. Marketing Strategy
        • 18.3.22.6.2. Product Strategy
        • 18.3.22.6.3. Channel Strategy

19. Assumptions and Acronyms Used

20. Research Methodology

List of Tables

  • Table 01: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Product
  • Table 02: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by End User
  • Table 03: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Region
  • Table 04: North America Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Product
  • Table 05: North America Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
  • Table 06: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Product
  • Table 07: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
  • Table 08: Europe Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Product
  • Table 09: Europe Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
  • Table 10: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Product
  • Table 11: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
  • Table 12: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Product
  • Table 13: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User

List of Figures

  • Figure 01: Global Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017-2021
  • Figure 02: Global Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032
  • Figure 03: Global Oncology Mice Models Market Absolute $ Opportunity, 2022-2032
  • Figure 04: Global Oncology Mice Models Market Share Analysis (%) By Product, 2022 & 2032
  • Figure 05: Global Oncology Mice Models Market Y-o-Y Growth (%) By Product, 2022- 2032
  • Figure 06: Global Oncology Mice Models Market Attractiveness Analysis, By Product
  • Figure 07: Global Oncology Mice Models Market Share Analysis (%) By End User, 2022 & 2032
  • Figure 08: Global Oncology Mice Models Market Y-o-Y Growth (%) By End User, 2022-2032
  • Figure 09: Global Oncology Mice Models Market Attractiveness Analysis, By End User
  • Figure 10: Global Oncology Mice Models Market Share Analysis (%) By Region, 2022 & 2032
  • Figure 11: Global Oncology Mice Models Market Y-o-Y Growth (%) By Region, 2022-2032
  • Figure 12: Global Oncology Mice Models Market Attractiveness Analysis, By Region
  • Figure 13: North America Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F)
  • Figure 14: North America Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022
  • Figure 15: North America Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022
  • Figure 16: North America Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017-2021
  • Figure 17: North America Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032
  • Figure 18: North America Oncology Mice Models Market Attractiveness Analysis, By Product
  • Figure 19: North America Oncology Mice Models Market Attractiveness Analysis, By End User
  • Figure 20: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F)
  • Figure 21: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022
  • Figure 22: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022
  • Figure 23: Latin America Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017-2021
  • Figure 24: Latin America Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032
  • Figure 25: Latin America Oncology Mice Models Market Attractiveness Analysis, By Product
  • Figure 26: Latin America Oncology Mice Models Market Attractiveness Analysis, By End User
  • Figure 27: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F)
  • Figure 28: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022
  • Figure 29: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022
  • Figure 30: Europe Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017-2021
  • Figure 31: Europe Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032
  • Figure 32: Europe Oncology Mice Models Market Attractiveness Analysis, By Product
  • Figure 33: Europe Oncology Mice Models Market Attractiveness Analysis, By End User
  • Figure 35: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022
  • Figure 36: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022
  • Figure 37: Asia Pacific Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017-2021
  • Figure 38: Asia Pacific Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032
  • Figure 39: Asia Pacific Oncology Mice Models Market Attractiveness Analysis, By Product
  • Figure 40: Asia Pacific Oncology Mice Models Market Attractiveness Analysis, By End User
  • Figure 41: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F)
  • Figure 42: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022
  • Figure 43: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022
  • Figure 44: Middle East and Africa (MEA) Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017-2021
  • Figure 45: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032
  • Figure 46: Middle East and Africa (MEA) Oncology Mice Models Market Attractiveness Analysis, By Product
  • Figure 47: Middle East and Africa (MEA) Oncology Mice Models Market Attractiveness Analysis, By End User
  • Figure 48: U.S. Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 49: U.S. Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 50: Canada Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 51: Canada Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 52: Mexico Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 53: Mexico Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 54: Brazil Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 55: Brazil Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 56: India Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 57: India Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 58: China Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 59: China Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 60: Japan Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 61: Japan Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 62: Germany Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 63: Germany Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 64: France Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 65: France Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 66: Italy Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 67: Italy Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 68: Russia Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 69: Russia Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 70: GCC Countries Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 71: GCC Countries Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 72: South Africa Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 73: South Africa Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032